{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T11:39:17Z","timestamp":1774611557855,"version":"3.50.1"},"reference-count":42,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2024,10,26]],"date-time":"2024-10-26T00:00:00Z","timestamp":1729900800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82101888"],"award-info":[{"award-number":["82101888"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82201989"],"award-info":[{"award-number":["82201989"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shanghai Commission of Science and Technology","award":["21Y11909100"],"award-info":[{"award-number":["21Y11909100"]}]},{"name":"Fellowship of China Postdoctoral Science Foundation","award":["2022T150134"],"award-info":[{"award-number":["2022T150134"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Idiopathic retroperitoneal fibrosis (iRPF) can lead to irreversible kidney damage. This study aimed to investigate predictors of irreversible renal dysfunction in patients with iRPF.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Eighty-three patients with newly diagnosed iRPF were enrolled between January 2010 and September 2022 at Zhongshan Hospital of Fudan University, including 60 in the training set and 23 in the validation set. They were regularly contacted or followed up via outpatient examinations by specialist doctors, who documented their condition and treatment progress. Predictors of irreversible renal dysfunction were identified using univariate and multivariate regression, logistic model, and receiver operating curve analyses.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In the training set, over a median follow-up of 29\u2009months, 16.7% of patients had an estimated glomerular filtration rate (eGFR) of &amp;lt;60\u2009ml\/min\/1.73 m2 at the last follow-up, and 25% had hydronephrosis or required prolonged double-J stents. A prognostic score was developed by assigning 1, 1, and 2 points for peripheral CD19+ B cells &amp;lt;9.3%, serum creatinine (sCr) \u2265120\u2009\u00b5mol\/L, and no response at 6\u2009months, respectively. A score of \u22652 for predicting irreversible renal dysfunction had sensitivity and specificity of 100% and 92%, respectively. In the validation set, 21.7% of patients suffered from irreversible renal dysfunction. The sensitivity and specificity for predicting irreversible renal dysfunction were 100% and 94.4%, respectively.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>A prognostic score based on factors including CD19+ B cells &amp;lt;9.3% and sCr \u2265120\u2009\u00b5mol\/L at baseline, and no response at 6\u2009months, is suitable for predicting irreversible renal dysfunction in iRPF.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keae565","type":"journal-article","created":{"date-parts":[[2024,10,26]],"date-time":"2024-10-26T16:52:12Z","timestamp":1729961532000},"page":"2855-2861","source":"Crossref","is-referenced-by-count":1,"title":["Predictors of irreversible renal dysfunction in patients with idiopathic retroperitoneal fibrosis"],"prefix":"10.1093","volume":"64","author":[{"given":"Zongfei","family":"Ji","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Zhongshan Hospital, Fudan University , Shanghai,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Zhongshan Hospital, Fudan University , Shanghai,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lijuan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Xiamen Branch, Zhongshan Hospital, Fudan University , Xiamen,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiufang","family":"Kong","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Zhongshan Hospital, Fudan University , Shanghai,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7747-7788","authenticated-orcid":false,"given":"Lindi","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Zhongshan Hospital, Fudan University , Shanghai,","place":["China"]},{"name":"Evidence-Based Medicine Center, Fudan University , Shanghai,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,10,26]]},"reference":[{"key":"2025050316133768600_keae565-B1","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1681\/ASN.2015101110","article-title":"Idiopathic retroperitoneal fibrosis","volume":"27","author":"Vaglio","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"2025050316133768600_keae565-B2","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0140-6736(06)68035-5","article-title":"Retroperitoneal fibrosis","volume":"367","author":"Vaglio","year":"2006","journal-title":"Lancet"},{"key":"2025050316133768600_keae565-B3","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/MD.0b013e3181afc420","article-title":"Idiopathic retroperitoneal fibrosis: prospective evaluation of incidence and clinicoradiologic presentation","volume":"88","author":"van Bommel","year":"2009","journal-title":"Medicine (Baltimore)"},{"key":"2025050316133768600_keae565-B4","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/S0140-6736(04)16100-X","article-title":"Asbestos exposure as a risk factor for retroperitoneal fibrosis","volume":"363","author":"Uibu","year":"2004","journal-title":"Lancet"},{"key":"2025050316133768600_keae565-B5","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.revmed.2014.10.008","article-title":"Idiopathic and secondary forms of retroperitoneal fibrosis: a diagnostic approach","volume":"36","author":"Urban","year":"2015","journal-title":"Rev Med Interne"},{"key":"2025050316133768600_keae565-B6","doi-asserted-by":"crossref","first-page":"e72-5","DOI":"10.1086\/433189","article-title":"Tuberculosis as a trigger of retroperitoneal fibrosis","volume":"41","author":"Greco","year":"2005","journal-title":"Clin Infect Dis"},{"key":"2025050316133768600_keae565-B7","first-page":"187","article-title":"Drug-induced retroperitoneal fibrosis: short aetiopathogenetic note, from the past times of ergot-derivatives large use to currently applied bio-pharmacology","volume":"36","author":"Alberti","year":"2015","journal-title":"G Chir"},{"key":"2025050316133768600_keae565-B8","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/iju.14218","article-title":"Current approach to diagnosis and management of retroperitoneal fibrosis","volume":"27","author":"Tanaka","year":"2020","journal-title":"Int J Urol"},{"key":"2025050316133768600_keae565-B9","doi-asserted-by":"crossref","first-page":"423","DOI":"10.2214\/AJR.07.3629","article-title":"Retroperitoneal fibrosis: a review of clinical features and imaging findings","volume":"191","author":"Cronin","year":"2008","journal-title":"AJR Am J Roentgenol"},{"key":"2025050316133768600_keae565-B10","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1097\/PAS.0b013e3181b72882","article-title":"Retroperitoneal fibrosis: a clinicopathologic study with respect to immunoglobulin G4","volume":"33","author":"Zen","year":"2009","journal-title":"Am J Surg Pathol"},{"key":"2025050316133768600_keae565-B11","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1097\/MD.0b013e318289610f","article-title":"Rethinking Ormond\u2019s disease: \u201cidiopathic\u201d retroperitoneal fibrosis in the era of IgG4-related disease","volume":"92","author":"Khosroshahi","year":"2013","journal-title":"Medicine (Baltimore)"},{"key":"2025050316133768600_keae565-B12","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1007\/s00296-013-2936-4","article-title":"Idiopathic retroperitoneal fibrosis: IgG4 infiltration in a cohort of Spanish patients","volume":"34","author":"Fernandez-Codina","year":"2014","journal-title":"Rheumatol Int"},{"key":"2025050316133768600_keae565-B13","doi-asserted-by":"crossref","first-page":"194","DOI":"10.3109\/14397595.2014.931908","article-title":"Clinicopathologic characteristics of IgG4-related retroperitoneal fibrosis among patients initially diagnosed as having idiopathic retroperitoneal fibrosis","volume":"25","author":"Koo","year":"2015","journal-title":"Mod Rheumatol"},{"key":"2025050316133768600_keae565-B14","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/S0140-6736(11)60934-3","article-title":"Prednisone versus tamoxifen in patients with idiopathic retroperitoneal fibrosis: an open-label randomised controlled trial","volume":"378","author":"Vaglio","year":"2011","journal-title":"Lancet"},{"key":"2025050316133768600_keae565-B15","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1053\/j.ajkd.2007.02.268","article-title":"Long-term renal and patient outcome in idiopathic retroperitoneal fibrosis treated with prednisone","volume":"49","author":"van Bommel","year":"2007","journal-title":"Am J Kidney Dis"},{"key":"2025050316133768600_keae565-B16","doi-asserted-by":"crossref","first-page":"e0245601","DOI":"10.1371\/journal.pone.0245601","article-title":"Clinical characteristics of IgG4-related retroperitoneal fibrosis versus idiopathic retroperitoneal fibrosis","volume":"16","author":"Wang","year":"2021","journal-title":"PLoS One"},{"key":"2025050316133768600_keae565-B17","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1464-410X.2006.06210.x","article-title":"Idiopathic retroperitoneal fibrosis: the case for nonsurgical treatment","volume":"98","author":"Ilie","year":"2006","journal-title":"BJU Int"},{"key":"2025050316133768600_keae565-B18","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1038\/sj.ki.5002427","article-title":"Idiopathic retroperitoneal fibrosis: clinicopathologic features and differential diagnosis","volume":"72","author":"Corradi","year":"2007","journal-title":"Kidney Int"},{"key":"2025050316133768600_keae565-B19","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1007\/s00296-014-3002-6","article-title":"Retroperitoneal fibrosis: a clinical and outcome analysis of 58 cases and review of literature","volume":"34","author":"Liu","year":"2014","journal-title":"Rheumatol Int"},{"key":"2025050316133768600_keae565-B20","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s10157-019-01759-w","article-title":"Risk factors for relapse and long-term outcome of idiopathic retroperitoneal fibrosis","volume":"23","author":"Moriconi","year":"2019","journal-title":"Clin Exp Nephrol"},{"key":"2025050316133768600_keae565-B21","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1053\/j.ajkd.2019.04.020","article-title":"Idiopathic retroperitoneal fibrosis: long-term risk and predictors of relapse","volume":"74","author":"Raffiotta","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"2025050316133768600_keae565-B22","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/bju.13061","article-title":"A lot of questions (and a few answers \u2026) in retroperitoneal fibrosis","volume":"117","author":"Fernando","year":"2016","journal-title":"BJU Int"},{"key":"2025050316133768600_keae565-B23","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1007\/s11255-017-1608-9","article-title":"Idiopathic retroperitoneal fibrosis: clinical features and long-term renal function outcome","volume":"49","author":"Zahran","year":"2017","journal-title":"Int Urol Nephrol"},{"key":"2025050316133768600_keae565-B24","doi-asserted-by":"crossref","first-page":"297","DOI":"10.4065\/mcp.2010.0663","article-title":"Idiopathic retroperitoneal fibrosis: a retrospective review of clinical presentation, treatment, and outcomes","volume":"86","author":"Kermani","year":"2011","journal-title":"Mayo Clin Proc"},{"key":"2025050316133768600_keae565-B25","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s10067-010-1580-6","article-title":"Idiopathic retroperitoneal fibrosis (RPF): clinical features of 61 cases and literature review","volume":"30","author":"Li","year":"2011","journal-title":"Clin Rheumatol"},{"key":"2025050316133768600_keae565-B26","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1148\/rg.334125081","article-title":"Chronic fibrosing conditions in abdominal imaging","volume":"33","author":"George","year":"2013","journal-title":"Radiographics"},{"key":"2025050316133768600_keae565-B27","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1148\/rg.332125085","article-title":"Retroperitoneal fibrosis: role of imaging in diagnosis and follow-up","volume":"33","author":"Caiafa","year":"2013","journal-title":"Radiographics"},{"key":"2025050316133768600_keae565-B28","doi-asserted-by":"crossref","first-page":"357071","DOI":"10.1155\/2012\/357071","article-title":"Are classification criteria for IgG4-RD now possible? The concept of IgG4-related disease and proposal of comprehensive diagnostic criteria in Japan","volume":"2012","author":"Okazaki","year":"2012","journal-title":"Int J Rheumatol"},{"key":"2025050316133768600_keae565-B29","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1080\/14397595.2020.1859710","article-title":"The 2020 revised comprehensive diagnostic (RCD) criteria for IgG4-RD","volume":"31","author":"Umehara","year":"2021","journal-title":"Mod Rheumatol"},{"key":"2025050316133768600_keae565-B30","first-page":"871","article-title":"Computed tomography parameters can be used as predictive markers for the improvement of renal function in patients with retroperitoneal fibrosis","volume":"33","author":"Gao","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"2025050316133768600_keae565-B31","doi-asserted-by":"crossref","first-page":"825","DOI":"10.7326\/0003-4819-158-11-201306040-00007","article-title":"Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline","volume":"158","author":"Stevens","year":"2013","journal-title":"Ann Intern Med"},{"key":"2025050316133768600_keae565-B32","doi-asserted-by":"crossref","first-page":"e12631","DOI":"10.1097\/MD.0000000000012631","article-title":"Rituximab for idiopathic and IgG4-related retroperitoneal fibrosis","volume":"97","author":"Wallwork","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"2025050316133768600_keae565-B33","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s41927-020-00140-9","article-title":"Use of rituximab in idiopathic retroperitoneal fibrosis","volume":"4","author":"Boyeva","year":"2020","journal-title":"BMC Rheumatol"},{"key":"2025050316133768600_keae565-B34","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1136\/annrheumdis-2014-206605","article-title":"Rituximab for IgG4-related disease: a prospective, open-label trial","volume":"74","author":"Carruthers","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2025050316133768600_keae565-B35","doi-asserted-by":"crossref","first-page":"e0183844","DOI":"10.1371\/journal.pone.0183844","article-title":"Long-term efficacy and safety of rituximab in IgG4-related disease: data from a French nationwide study of thirty-three patients","volume":"12","author":"Ebbo","year":"2017","journal-title":"PLoS One"},{"key":"2025050316133768600_keae565-B36","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1038\/modpathol.2012.72","article-title":"Consensus statement on the pathology of IgG4-related disease","volume":"25","author":"Deshpande","year":"2012","journal-title":"Mod Pathol"},{"key":"2025050316133768600_keae565-B37","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1016\/S2665-9913(19)30017-7","article-title":"Management of IgG4-related disease","volume":"1","author":"Zhang","year":"2019","journal-title":"Lancet Rheumatol"},{"key":"2025050316133768600_keae565-B38","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.3389\/fimmu.2020.01272","article-title":"In vitro IL-6\/IL-6R trans-signaling in fibroblasts releases cytokines that may be linked to the pathogenesis of IgG4-related disease","volume":"11","author":"Zongfei","year":"2020","journal-title":"Front Immunol"},{"key":"2025050316133768600_keae565-B39","first-page":"62","article-title":"Pro-fibrotic effect of IL-6 via aortic adventitial fibroblasts indicates IL-6 as a treatment target in Takayasu arteritis","volume":"36","author":"Kong","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"2025050316133768600_keae565-B40","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1002\/art.38032","article-title":"Interleukin-6 as an inflammatory mediator and target of therapy in chronic periaortitis","volume":"65","author":"Vaglio","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2025050316133768600_keae565-B41","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003007","article-title":"Pilot study of tocilizumab monotherapy for active chronic periaortitis","volume":"9","author":"Wang","year":"2023","journal-title":"RMD Open"},{"key":"2025050316133768600_keae565-B42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/20406223211028776","article-title":"Improved clinical outcomes of tocilizumab versus cyclophosphamide for IgG4-related disease: insights from a prospective IgG4-related disease registry","volume":"12","author":"Zongfei","year":"2021","journal-title":"Ther Adv Chronic Dis"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keae565\/60254420\/keae565.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/5\/2855\/60254420\/keae565.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/5\/2855\/60254420\/keae565.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T20:13:58Z","timestamp":1746303238000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/64\/5\/2855\/7845265"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,26]]},"references-count":42,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,10,26]]},"published-print":{"date-parts":[[2025,5,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keae565","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,5]]},"published":{"date-parts":[[2024,10,26]]}}}